| [1] |
Perugorria MJ, Masyuk TV, Marin JJ, et a1．Polycystic liver diseases: advanced insights into the molecular mechanisms[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(12):750-761．
|
| [2] |
Santos-Laso A, Izquierdo-Sánchez L, Lee-Law PY, et a1. New advances in polycystic liver diseases[J]. Semin Liver Dis, 2017, 37(1):45-55.
|
| [3] |
Smith TW Jr, Goldberg A, Lu AD. Preserving the organ donor pool and suprahepatic vena cava: case series of transverse hepatectomy for polycystic liver disease[J]. Ann Hepatol, 2019: pii:S1665-2681(19)32224-0.
|
| [4] |
Zhang JL, Yuan K, Wang MQ, et a1. Transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2-year follow-up[J]. Chin Med J (Engl), 2017, 130(16):1938-1944.
|
| [5] |
Yang J, Ryu H, Han M, et a1. Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease[J]. Hepatol Res, 2016, 46(2):183-191.
|
| [6] |
Sakuhara Y, Nishio S, Hattanda F, et a1. Initial experience with the use of tris-acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver[J]. Clin Exp Nephrol, 2019, 23(6):825-833.
|
| [7] |
van Aerts RMM, van de Laarschot LFM, Banales JM, et al. Clinical management of polycystic liver disease[J]. J Hepatol, 2018, 68(4): 827-837．
|
| [8] |
Park HC, Kim CW, Ro H, et al. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients[J]. J Korean Med Sci, 2009, 24(1): 57-61.
|
| [9] |
陈威，张海斌，付雍，等．肝部分切除联合囊肿广泛开窗术治疗严重成人多囊肝病的疗效及临床分型对其预后的影响[J]．中华肝脏病杂志, 2010(1): 41-44．
|
| [10] |
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2017, 377(20):1930-1942.
|
| [11] |
Mancinelli R, Franchitto A, Glaser S, et al. Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease[J]. Lab Invest, 2016, 96(11):1147-1155.
|
| [12] |
Masyuk AI, Masyuk TV, Lorenzo Pisarello MJ, et al. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target[J]. Hepatology, 2018, 67(3):1088-1108.
|
| [13] |
Takenaka T, Miura S, Kitajima M. The management of polycystic liver disease by tolvaptan [J]. Clin Mol Hepatol, 2019, DOI: 10.3350/cmh.2019.0026[Epub ahead of print]. |
| [14] |
Gevers TJ, Inthout J, Caroli A, et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data[J]. Gastroenterology, 2013, 145(2): 357-365, e1-2.
|
| [15] |
Khan S, Dennison A, Garcea G. Medical therapy for polycystic liver disease[J]. Ann R Coll Surg Engl, 2016, 98(1):18-23.
|
| [16] |
Gevers TJ, Drenth JP. Somatostatin analogues for treatment of polycystic liver disease[J]. Curr Opin Gastroenterol, 2011, 27(3): 294-300.
|
| [17] |
Masyuk TV, Masyuk AI, LaRusso NF. Therapeutic targets in polycystic liver disease[J]. Curr Drug Targets, 2017, 18(8):950-957.
|
| [18] |
Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients[J]. J Am Soc Nephrol, 2008(19):631-638.
|
| [19] |
Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease[J]. N Engl Med，2010(363):820-829.
|
| [20] |
Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease[J]. N Engl Med, 2010(363):830-840.
|
| [21] |
Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease[J]. N Engl Med, 2010(363):879-881.
|
| [22] |
Renken C, Fischer DC, Kundt G, et al. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats[J]. Nephrol Dial Transplant, 2011, 26(1):92-100.
|
| [23] |
Munoz-Garrido P, Marin JJ, Perugorria MJ, et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease[J]. J Hepatol, 2015, 63(4):952-961.
|
| [24] |
Perugorria MJ, Labiano I, Esparza-Baquer A, et al. Bile acids in polycystic liver diseases: triggers of disease progression and potential solution for treatment[J]. Dig Dis, 2017, 35(3):275-281.
|
| [25] |
D'Agnolo HM, Kievit W, Takkenberg RB, et al. Ursodeoxycholic acid in advanced polycystic liver disease:a phase 2 multicenter randomized controlled trial[J]. J Hepatol, 2016, 65(3):601-607.
|